Identification of KRT16 as a Target of an Autoantibody Response in Complex Regional Pain Syndrome.

CONCLUSIONS: Pursuing autoimmune contributions to CRPS provides a novel approach to understanding the condition and may allow the development of mechanism-based therapies. The identification of autoantibodies against KRT16 as a biomarker in mice and in humans is a critical step towards these goals, and towards redefining CRPS as having an autoimmune etiology.
PMID: 27773721 [PubMed - as supplied by publisher]

Source: Experimental Neurology - October 19, 2016 Category: Neurology Authors: Tajerian M, Hung V, Khan H, Lahey LJ, Sun Y, Birklein F, Krämer HH, Robinson WH, Kingery WS, Clark JD Tags: Exp Neurol Source Type: research